Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (141-150 of 232) with videos related to

Pageof 24
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesionsLori J Wirth, Jeffrey F Krane, Yi Li, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Cancer Immunology Research|July 5, 2014
Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survivalWilliam E Carson, Joseph M Unger, Jeffrey A Sosman, et al.
Leukemia|January 25, 2020
Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AMLLinde M Morsink, Megan Othus, Evandro D Bezerra, et al.
Haematologica|July 11, 2020
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibilityMary-Elizabeth M Percival, Megan Othus, Sarah Mirahsani, et al.
British Journal of Haematology|October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow, Megan Othus, Larry D Cripe, et al.
Leukemia|January 21, 2022
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignanciesNoam E Kopmar, Megan Othus, Kelda M Gardner, et al.
Leukemia|October 14, 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsMegan Othus, Elihu H Estey, Guillermo Garcia-Manero, et al.
Cancer|October 10, 2013
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trialsWilliam G Woods, Anna R K Franklin, Todd A Alonzo, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Pageof 24

Showing results (141-150 of 232) with videos related to

Sort By:
Pageof 24
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesionsLori J Wirth, Jeffrey F Krane, Yi Li, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Cancer Immunology Research|July 5, 2014
Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survivalWilliam E Carson, Joseph M Unger, Jeffrey A Sosman, et al.
Leukemia|January 25, 2020
Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AMLLinde M Morsink, Megan Othus, Evandro D Bezerra, et al.
Haematologica|July 11, 2020
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibilityMary-Elizabeth M Percival, Megan Othus, Sarah Mirahsani, et al.
British Journal of Haematology|October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow, Megan Othus, Larry D Cripe, et al.
Leukemia|January 21, 2022
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignanciesNoam E Kopmar, Megan Othus, Kelda M Gardner, et al.
Leukemia|October 14, 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsMegan Othus, Elihu H Estey, Guillermo Garcia-Manero, et al.
Cancer|October 10, 2013
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trialsWilliam G Woods, Anna R K Franklin, Todd A Alonzo, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Pageof 24